MAR001 successfully lowered triglyceride levels in the phase IIa trial, but whether this reduces CV risk isn’t yet known.

An early stop of the OptimPacing trial may have exaggerated the benefits, but experts say many EPs have already made the ...

These findings suggest cautious statin discontinuation in primary prevention only after shared decision-making,” Nicolas ...

The supervised intervention seemed to be durable, suggesting patients learned things that may help them in the long term.

Patients had fewer MACE over 4 years compared with a standard systolic target, but some had worsened renal function.

The drug failed to reduce CV events in the RCT, but it’s clear many still hold out hope for the inflammatory hypothesis.

A “successful” procedure may have a different meaning to the heart team than to the patient, Misty Theriot stressed.

One trial does not disprove the concept that lowering Lp(a) can reduce CV risk, Steven Nissen stresses, with “more work to do ...

SAN DIEGO, CA—The novel ProtEmbo device (Protembis) for cerebral embolic protection (CEP) during TAVI is safe to use but does ...

At 6 months, the win ratio favored the device over optimal medical therapy, in large part driven by improved quality of life.

The IRIS-MAIN registry results did show some differences in nonfatal outcomes like stroke, MI, and revascularization.

Underdiagnosis and undertreatment likely drive the profound effects observed in certain populations, says Juan Granada.